Page 91 - Read Online

Page 18 of 18 Huang et al. J Cancer Metastasis Treat 2019;5:34 I http://dx.doi.org/10.20517/2394-4722.2018.94

106. Messaritakis I, Politaki E, Plataki M, Karavassilis V, Kentepozidis N, et al. Heterogeneity of circulating tumor cells (CTCs) in patients
with recurrent small cell lung cancer (SCLC) treated with pazopanib. Lung Cancer 2017;104:16-23.
107. Li Y, Gong J, Zhang Q, Lu Z, Gao J, et al. Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced
gastric cancer. Br J Cancer 2016;114:138-45.
108. Meulendijks D, de Groot JW, Los M, Boers JE, Beerepoot LV, et al. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine,
followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric
cancer: A multicenter phase 2 study. Cancer 2016;122:1434-43.
109. Pernot S, Badoual C, Terme M, Castan F, Cazes A, et al. Dynamic evaluation of circulating tumour cells in patients with advanced gastric
and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. Eur J Cancer 2017;79:15-22.
110. Kubisch I, de Albuquerque A, Schuppan D, Kaul S, Schaich M, et al. Prognostic Role of a Multimarker Analysis of Circulating Tumor
Cells in Advanced Gastric and Gastroesophageal Adenocarcinomas. Oncology 2015;89:294-303.
111. Brungs D, Lynch D, Luk AW, Minaei E, Ranson M, et al. Cryopreservation for delayed circulating tumor cell isolation is a valid strategy
for prognostic association of circulating tumor cells in gastroesophageal cancer. World J Gastroenterol 2018;24:810-8.
112. Sclafani F, Smyth E, Cunningham D, Chau I, Turner A, et al. A pilot study assessing the incidence and clinical significance of circulating
tumor cells in esophagogastric cancers. Clin Colorectal Cancer 2014;13:94-9.